Systemic therapy in metastatic renal cell carcinoma

PURPOSE: Current systemic treatment of targeted therapies, namely the vascular endothelial growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitors, have improved progression-free survival and replaced non-specific immunother...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Urol
Main Authors: Bedke, Jens, Gauler, Thomas, Grünwald, Viktor, Hegele, Axel, Herrmann, Edwin, Hinz, Stefan, Janssen, Jan, Schmitz, Stephan, Schostak, Martin, Tesch, Hans, Zastrow, Stefan, Miller, Kurt
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2016
Assuntos:
Invited Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5272893/
https://ncbi.nlm.nih.gov/pubmed/27277600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-016-1868-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados